

Investor Relations Brief

4 2025
April



Business Division Progress Update


Molecular Diagnostics

From March 17 to 21, Bioneer hosted a five-day training program at its headquarters for engineers from its new distributors in Hong Kong and Côte d'Ivoire. The training focused on helping partners deliver faster and more effective service and support in their local markets.

A highlight was the in-depth training on IRON-qPCR™, Bioneer's point-of-care molecular diagnostics platform, aimed at strengthening technical expertise in real-world settings. As global demand rises for Bioneer's quantitative diagnostic kits—especially its WHO PQ-certified HIV viral load kit—participants also received training on proper product use and quality control.

James C.K, Business Director of the Hong Kong distributor, shared his optimism, calling IRON-qPCR™ “a game-changer in molecular diagnostics.”

A Bioneer official added, “This training strengthens our global partners' capabilities and supports our mission to deliver fast, accurate molecular diagnostics worldwide.”



Business Division Progress Update



Molecular Diagnostics

From March 5 to 7, Bioneer participated in “Medical Japan Osaka 2025,” holding over 50 meetings with more than 300 visitors to showcase its on-site molecular diagnostics platform, IRON-qPCR™.

Key highlights included strong interest in IRON-qPCR™-based test kits for hair loss diagnostics, tuberculosis and multidrug-resistant TB, and carbapenem resistance. Bioneer also introduced its innovative technology capable of quantifying hair loss-related mRNA in hair follicles within just 40 minutes.

The company recently received MDSAP (Medical Device Single Audit Program) certification from the U.S., Canada, Australia, and Brazil for its quality management system, with Japan’s certification completed in October 2024.

Japan’s molecular diagnostics market is estimated at KRW 950 billion—more than 3.5 times larger than Korea’s—making it a high-potential target for Bioneer’s business expansion.



Business Division Progress Update

Molecular Diagnostics

Bioneer has applied for domestic manufacturing approval from the Ministry of Food and Drug Safety (MFDS) in March for its HBV Quantification Kit, designed to monitor treatment efficacy and prognosis in hepatitis B patients. The kit is compatible with Bioneer's next-generation fully automated molecular diagnostics platform, ExiStation™ FA 96.

Developed as part of a national R&D initiative since 2022, the HBV kit recently completed clinical performance trials at a top-tier general hospital in Korea. The test uses freeze-dried, single-tube reagents for enhanced stability and incorporates Bioneer's patented HotStart™ PCR technology, enabling sensitive detection of low viral loads.

ExiStation™ FA 96 fully automates the diagnostic workflow—from tube decapping and sample dispensing to nucleic acid extraction and real-time PCR—delivering results in under two hours, a major improvement over the typical four-hour process. The platform also improves operator safety by automating tube handling.

Bioneer plans to submit applications for HIV-1 and HCV quantification kits within April, targeting regulatory approval in the second half of the year. The domestic molecular diagnostics market for HIV, HBV, and HCV was valued at KRW 33.87 billion in 2023, accounting for about 15% of the overall market.



Business Division Progress Update

CosmeRNA

CosmeRNA is actively expanding its overseas B2C marketing to boost brand awareness, focusing on targeted digital advertising. As part of this strategy, the brand has launched campaigns on well-known hair loss forums to reach customers dealing with hair loss concerns.

Recently, CosmeRNA secured ad placement on “HAIR LOSS CURE 2020,” one of the leading U.S.-based hair loss communities, marking its official introduction to American audiences. The company is also in active discussions with “MISSYUSA,” the largest Korean-American women’s community in North America, anticipating high brand exposure and potential sales growth among Korean customers unfamiliar with the brand.

Beyond these two platforms, CosmeRNA plans to expand across other niche communities and digital channels, including influencer marketing and video content, to reach broader general audiences in North America.

Recognizing CosmeRNA’s growth potential, the city of Daejeon has expressed strong support for its global expansion and plans to provide further assistance going forward.

Hair Loss Cure 2020

eR on Naturally Occurring Sugar Grows Hair in Mice

Pinotq on Pelage Pharmaceuticals Phase 2 Trials for PP405 Started

Dobronx on Naturally Occurring Sugar Grows Hair in Mice

HOME ABOUT PRODUCTS BEST LASER HAIR GROWTH DEVICES HAIR RESEARCH BEST DANDRUFF SHAMPOOS CONTACT US PRIVACY POLICY

gen receptor antagonist) as a cosmetic on Amazon.

- [KX-826 1.0%.](#)
- [KX-826 0.5%.](#)

Update March 21, 2025

Phase III Clinical Trial Of KX-826 Reaches Primary Endpoint

Kintor Pharmaceutical [just announced](#) that the long-term safety Phase III clinical trial of its first-in-class KX-826 (pyrilutamide) tincture for the treatment of androgenetic alopecia has reached its primary endpoint. The results are very good, the safety profile is excellent and therefore the company’s stock price went up a stunning 51% so far today. The first person in this 52-week trial was enrolled on 19 July 2023. The results demonstrated excellent safety and efficacy. Key highlights:

- 46% of patients saw a ≥ 10 hairs/cm² change in total area hair count (TAHC) from baseline.
- 20% of patients saw a ≥ 20 hairs/cm² change in TAHC.

Note that this clinical trial involves a total of 16 clinical research centers in China. It seems like earlier “pre” primary endpoint positive results were also released last year (see my update from October 17, 2024).

Even better news is that this trial used KX-826 tincture 0.5% BID (twice per day) as the dosage. Kintor also began a Phase III trial for the higher-dose 1.0% at the beginning of 2025. That dose might give even better results.

Update January 28, 2025

RISK-FREE Online Telehealth Hair Loss Consultation
MedicalWellnessCenter.com

WORLDWIDE LEADER IN THE BEST RESEARCH PRODUCTS

- WORLDWIDE SHIPPING
- DELIVERY GUARANTEE
- 3RD PARTY TESTED

SHOP NOW
www.anageninc.com

USE COUPON CODE: **ANAGENTO** FOR 10% OFF!
For research use only

THE WONDERFUL EFFECTS OF THE AWARD
winning product in 2024 Cosmoprof Hair category

Business Division Progress Update

CosmeRNA

CosmeRNA is currently conducting four human application studies both in Korea and internationally to validate the product's sustained efficacy and safety. Some of these trials specifically target women, aligning with the brand's core customer segment.

One such female-focused clinical trial began in November 2024 at SkinMed, a dermatological testing institution based in Daejeon, Korea. All participants are women, and the trial is scheduled for completion by mid-July 2025. Through these trials, CosmeRNA aims to secure credible scientific data, enhancing product trust and strengthening its competitive edge in both domestic and global markets.



Business Division Progress Update


CosmeRNA

To expand its global B2B distribution network and boost brand awareness, CosmeRNA is actively participating in international beauty expos. From March 20–23, the brand joined *Cosmoprof Worldwide Bologna 2025* in Italy, operating a booth to promote its specialized hair loss care products to local buyers and beauty professionals.

The exhibition helped raise brand awareness for salon-exclusive products among global hair and beauty experts and included meetings with key European buyers and distributors, confirming strong B2B partnership potential in the region.

Looking ahead, CosmeRNA will attend *Dubai Derma 2025* from April 14–16, co-hosting a booth with UAE-exclusive distributor ATLAS MEDICAL LLC. The brand will engage local medical professionals and distributors across the Middle East.

On the second day of Dubai Derma 2025, CosmeRNA will a workshop with about 50 regional dermatologists and KOLs to discuss clinical experiences and share feedback.



Business Division Progress Update

AceBiome

AceBiome participated in the world's largest natural products trade show, Natural Products Expo West 2025 (NPEW 2025), held in Anaheim, California, from March 5 to 7, with an independent booth.

Natural Products Expo West is a leading international event in the food and health supplement industries, drawing over 60,000 buyers, consumers, and professionals each year. At the show, AceBiome presented its key product lineup directly to global buyers, signaling a full-scale push into international markets.

The company showcased flagship products including BNRThin, a probiotic recognized by the Korean Ministry of Food and Drug Safety for body fat reduction; BNRQueen, a multifunctional probiotic designed for menopausal women; and AnaParactin, a joint health supplement. These scientifically validated, lifestyle-targeted solutions attracted strong interest from attendees, particularly for their differentiated functionality.

AceBiome's booth welcomed visitors from the U.S., Europe, Latin America, and Asia. Buyers and distributors praised the company's evidence-based product development and consumer-oriented portfolio.

Through this expo, AceBiome aims to broaden connections with international distribution channels and will continue participating in major global exhibitions to expand its business and accelerate global market entry.



Business Division Progress Update

AceBiome

On March 27, health supplement company AceBiome held a donation ceremony in partnership with the Korea National Council on Social Welfare, providing approximately KRW 1.7 billion worth of products. The initiative aims to support the health of social welfare volunteers and encourage broader participation. The supplements will be distributed nationwide to help motivate and energize volunteers in the field.

Beyond this donation, AceBiome actively pursues corporate social responsibility through ongoing contributions to underserved communities and care facilities, including regular donations of health supplements. The company also runs the “Slim Donation” campaign, where consumers receive BNRThin in return for donating unused items like clothes or household goods, showcasing its diverse approach to giving back.

CEO Myunghee Kim stated, “It’s important for growing companies to embrace their social responsibilities. We plan to continue working closely with the Korea National Council on Social Welfare to explore additional programs that promote volunteerism and close welfare gaps.”

AceBiome launched BNRThin in 2018, Korea’s first probiotic approved by the Ministry of Food and Drug Safety for fat-reducing functionality. The company has since expanded its lineup to include BNRQueen for women’s health, AnaParactin for joint care, Etnacare for skin health, GoodBreath for oral health, and multivitamins. In 2024, its 8th year, AceBiome reported annual sales of KRW 268.8 billion, solidifying its position in the Korean health supplement market.



Business Division Progress Update


siRNAgen

Following the early completion of its Phase 1a study, siRNAgen Therapeutics has finalized clinical strategies for SRN-001 through consultations with domestic KOLs, aiming to begin global business development in 2026.

The upcoming Phase 1b trial will involve healthy adults and assess pharmacokinetics and safety through repeated IV dosing. A patient-based design was excluded based on IRB feedback requiring stronger benefit data. The trial builds on results from the Australian Phase 1a study and will evaluate AREG expression changes and safety. Participants with high AREG expression will be selected, and obesity-related metrics like InBody scans will be included to assess potential weight-loss effects.

Conducted in collaboration with Seoul National University's Department of Pharmacology, the trial is in active preparation, with the draft protocol and budget already completed. siRNAgen chose Korea over the U.S. due to advantages in cost and trial speed.

If IND approval is granted, it would mark Korea's first siRNA-based clinical trial, validating the SAMiRNA platform and positioning the company as a leader in the field. siRNAgen has already held a pre-consultation with the MFDS and plans a follow-up meeting in April. Success in Phase 1b could confirm SRN-001's potential for fibrosis and obesity treatment, while demonstrating SAMiRNA's platform value. The Phase 1a study results are being reviewed with Seoul National University Hospital and are expected to be submitted for publication in March.



33rd Annual Shareholders' Meeting

Bioneer Corp.

Bioneer successfully held its 33rd Annual General Meeting of Shareholders, reaffirming shareholders' strong interest and trust through active attendance.

The meeting included a report on 2024 business performance and the smooth approval of key agenda items. It also provided an opportunity to share Bioneer's mid- to long-term growth strategies and vision directly with shareholders.

A Q&A session allowed the company to sincerely address shareholders' questions and gather valuable feedback, strengthening communication and engagement.






Bioneer will continue to prioritize shareholder trust, maintaining transparent management and responsible decision-making to drive sustainable growth. The company also remains committed to open communication to ensure stable profitability and enhance corporate value.



33rd Annual Shareholders' Meeting

Bioneer Corp.

Results of Agenda Voting 33rd Annual Shareholders' Meeting



Shares Present 13,511,981 Shares

Attendance Rate 52.4%

